Gelonghui, May 20 | Lu Xin Venture Capital (600783.SH) said on the investor interactive platform that currently, the company involved in immunotherapy in the company's and equity fund investment projects is 3D Medicines. Currently, the company and equity fund have no cell therapy companies in the investment project.
鲁信创投(600783.SH)：目前公司及参股基金在投项目中暂无细胞疗法公司
Lu Xin Venture Capital (600783.SH): Currently, there are no cell therapy companies in the company and equity investment projects
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.